RecruitingNot ApplicableNCT05268120

MRSA Decolonization in Complicated Carriage

MRSA Decolonization in Complicated Carriage - Cluster Randomized Trial


Sponsor

Leiden University Medical Center

Enrollment

211 participants

Start Date

Jul 25, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

Multicenter open-label cluster randomized controlled trial determining the superiority of doxycycline-rifampicin compared to trimethoprim-rifampicin for the decolonization treatment of complicated MRSA carriership.


Eligibility

Min Age: 18 Years

Inclusion Criteria4

  • Age ≥18 years
  • Complicated MRSA carriership. Complicated carriership is defined as having one of the following features: (i) the presence of MRSA located at another site than the nose, (ii) an active infection with MRSA, (iii) in vitro resistance for mupirocin, (iv) active skin lesions, (v) foreign material that connects an internal body site with the outside (e.g., urine catheter, external fixation material), (vi) previously failure of decolonization treatment.
  • In case of none of the previously mentioned features, this is considered uncomplicated carriership.
  • \- The ability to provide informed consent for the use of their data.

Exclusion Criteria5

  • \- Presence of any iv-access, urinary catheters or drains (because of high risk of treatment failure)
  • Failure of previous decolonization attempt of complicated MRSA carriage
  • Allergy or other contra-indication to either doxycycline, rifampicin or trimethoprim (these patients will participate in the observational arm)
  • Previous participation in this study (every patient can only participate once)
  • Pregnancy

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGdoxycycline 200 mg q.d. - rifampicin 600mg b.i.d.

Both first choice treatments in Dutch guideline for MRSA decolonization

DRUGtrimethoprim 200mg b.i.d. - rifampicin 600mg b.i.d.

Both first choice treatments in Dutch guideline for MRSA decolonization


Locations(1)

LUMC

Leiden, Netherlands

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05268120


Related Trials